News & Events zu Genprex Inc (GNPX)GNPXGenprex Inc

Genprex Announces Results from Reqorsa Clinical Analysis

Genprex announced results from a translational analysis of patients treated with its lead drug candidate, Reqorsa - quaratusugene ozeplasmid -, a gene therapy product. The data suggest that increased TUSC2 expression, the tumor suppressor gene used in Reqorsa, is associated with a systemic transcriptional shift toward cellular maintenance, repair and quality control, a profile consistent with enhanced cellular resilience to aging-associated stress. The findings were presented in a poster at the Gerontological Society of America 2026 Annual Scientific Meeting November 4-7 in National Harbor, Maryland. TUSC2 is a mitochondrial calcium-regulating protein whose expression declines with age, including in the human brain and other metabolically active tissues. Researchers used Reqorsa, designed to restore tumor-suppressor function, to study the blood's transcriptional response to increased TUSC2.

Genprex Collaborates with Roche Diagnostics to Validate Biomarkers for NSCLC

Genprex (GNPX) announced its collaboration with Roche Diagnostics (RHHBY) to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer. Building on promising preclinical and clinical data, this collaboration intends to refine patient identification using TROP2 as a biomarker. The collaboration leverages Roche Diagnostics' expertise in assay development. Roche Diagnostics received U.S. FDA Breakthrough Device Designation for the first AI-driven companion diagnostic for NSCLC that uses a TROP2 score to evaluate NSCLC specimens, and Genprex will use the same antibody against TROP2 for its validation studies. This strategic alignment ensures consistency and builds upon established diagnostic methods. Genprex is expanding on its preclinical and clinical studies to potentially integrate TROP2 expression for patient selection in NSCLC clinical studies. Roche Diagnostics will perform the necessary assay validation using its TROP2 antibody. Genprex anticipates completing these validation studies by approximately the end of 2026, with subsequent integration into its NSCLC clinical program shortly thereafter, dependent on the results of the validation studies. This collaboration exemplifies Genprex's commitment to delivering innovation that enables more precise diagnosis and treatment strategies in oncology, ultimately aiming to improve outcomes for NSCLC patients.

Genprex Trading Halted, News Pending

Genprex trading halted, news pending